Weekly Briefing

Briefing for the week of November 3 – November 9, 2026

Coverage period: November 3, 2026 – November 9, 2026

Published November 9, 2026

CMS issued its final 2027 Medicare payment rules for hospital outpatient care and physician services on Nov. 4, cutting payment for 340B-acquired drugs to average sales price minus 28%, extending site-neutral payment to some imaging, and lowering the physician conversion factor by about 2%. In court, a Maryland federal judge lifted CMS's freeze on new ACA broker registrations during open enrollment. Oregon, Minnesota, New Mexico and Washington sued to block a federal threat to withhold existing Medicaid funds from states that decline to implement work requirements due Jan. 1, 2027. After the Nov. 3 midterms, Democratic gains in Congress are expected to bring oversight of Medicaid, drug-pricing and prior-authorization policy, but little immediate statutory change. KFF's updated analysis shows fewer Medicare Advantage plan choices and more counties with no drug-covering MA plan in 2027.

This Week

The Developments

Final rule

CMS finalizes 2027 hospital outpatient rule: 340B drugs paid at ASP minus 28%, site-neutral imaging, faster recoupment of prior 340B payments

Issued Nov 4, 2026; 340B payment cut and 2% remedy offset take effect Jan 1, 2027; hospital off-campus NPI and attestation requirements by Jan 1, 2028

What changed

CMS issued the calendar year 2027 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center final rule (CMS-1850-F). Per CMS's fact sheet, rates rise 2.3% for hospitals meeting quality reporting requirements (a 3.2% market basket update less a 0.9 percentage point productivity adjustment). Separately payable drugs acquired through the 340B program will be paid at average sales price (ASP) minus 28%, based on a CMS survey of hospital drug acquisition costs conducted Jan. 1 to April 7, 2026. CMS estimates the cut reduces Original Medicare drug payments by $4.35 billion and beneficiary payments by $1.1 billion in the first year, and that non-drug outpatient payments rise by an equivalent amount to keep the change budget neutral. The American Hospital Association reports the proposal was ASP minus 33.4% and that rural sole community hospitals, PPS-exempt cancer hospitals and children's hospitals are exempt. CMS also raises the offset used to recover an earlier 340B payment remedy from 0.5% to 2% starting in 2027 until $7.8 billion is recovered, which it expects in 2031. Separately, site-neutral payment now covers imaging without contrast at grandfathered off-campus hospital outpatient departments, paid at the physician fee schedule-equivalent rate, with rural sole community hospitals exempt; CMS estimates about $260 million in 2027 savings. Trade press reports eight more botulinum toxin injection codes will require prior authorization in hospital outpatient departments.

Why it matters

The 340B program lets safety-net hospitals buy outpatient drugs at a discount, so a lower Medicare payment rate for those drugs changes how much revenue they keep from them. Because the cut is budget neutral, the money is redistributed to non-drug services rather than saved, so who gains and who loses depends on each hospital's mix. Site-neutral payment narrows the higher rates hospitals receive for services that can be done in physician offices. All dollar figures are CMS's estimates and the hospital-group description is advocacy; the effect on hospitals and patients has not been measured. Sources conflict on the data behind the 340B rate: CMS's fact sheet points to its acquisition cost survey, while the AHA says CMS used HRSA ceiling price data instead.

  • Access
  • Affordability
Warrants deeper follow-up. Open the Federal Register document and the CMS final rule text to confirm the data basis for the 340B rate, exemptions and effective dates; watch for hospital lawsuits and for the fate of the separate 340B rebate pilot due to begin Jan 1, 2027. Federal Register document 2026-22739 (RFI on price transparency, prior authorization and EMTALA accreditation deeming) is not covered here.

Sources

Background from our research

Final rule

CMS finalizes 2027 physician fee schedule: conversion factor falls about 2% as a one-year increase expires

Issued Nov 4, 2026; generally effective Jan 1, 2027

What changed

CMS's fact sheet for the calendar year 2027 Medicare Physician Fee Schedule final rule sets the conversion factor at $32.63 for clinicians not in qualifying alternative payment models (down $0.77, or 2.31%, from $33.40) and $32.95 for qualifying APM participants (down $0.62, or 1.83%, from $33.57). CMS attributes the decline to expiry of a one-year 2.50% increase enacted in Public Law 119-21, partly offset by statutory updates of 0.25% and 0.75% and an estimated -0.12% work relative value adjustment. The add-on code G2211 becomes modifier B1, raising the associated office visit payment by 16%, and a new modifier B2 raises payment for the associated visit by 32% for practitioners in a Medicare Shared Savings Program ACO or a LEAD Model participant. CMS delays to Jan. 1, 2029 a restriction on remote patient monitoring vendors, and extends certain telehealth payment flexibilities for rural health clinics and FQHCs through Dec. 31, 2027. Medical Economics reports the cuts are deeper than the July proposal (1.68% and 1.19%) and that CMS scaled back a proposed same-day visit payment reduction from 50% to 20%.

Why it matters

Medicare fee schedule rates determine what physicians are paid for services to Medicare patients, so a reduction in the conversion factor bears on practice finances. The higher visit payment for ACO participants builds a payment advantage for clinicians in certain value-based arrangements. This summary rests on CMS's fact sheet and one trade-press report; specialty-level impacts and the effect on patient access were not reviewed, and the reduction is a projected change in payment rates, not measured access outcomes.

  • Access
  • Affordability
  • Reform
Warrants deeper follow-up. Read the Federal Register document and impact tables for specialty-level effects; confirm the same-day visit policy and ACO modifier details against the rule text.

Sources

Background from our research

Litigation

Oregon, Minnesota, New Mexico and Washington sue over threat to withhold Medicaid funds from states that decline work requirements

Filed Nov 5, 2026 (D. Or.); work requirements take effect Jan 1, 2027

What changed

The attorneys general of Oregon, Minnesota, New Mexico and Washington sued HHS and CMS in the U.S. District Court for the District of Oregon (Oregon v. Oz) on Nov. 5, 2026. They argue Congress cannot constitutionally coerce states into adopting the Medicaid work requirements in H.R. 1 by threatening to withhold existing Medicaid funding, relying on the Supreme Court's 2012 decision in NFIB v. Sebelius. The Oregon Department of Justice's case page says a motion for summary judgment and a motion for a preliminary injunction were filed with the complaint. Becker's Payer Issues, summarizing the complaint, reports that Oregon has 564,177 expansion adults, that this group accounts for about $5.1 billion (54%) of the state's federal Medicaid funding this fiscal year, and that a cited study estimates about 20% of Oregon's Medicaid enrollees would be disenrolled. A CMS spokesperson said the agency does not comment on pending litigation. This is separate from the multistate Massachusetts challenge in which a Boston judge ruled on Oct. 29 on the 'medically frail' exemption.

Why it matters

This suit challenges whether states can decline to implement the requirements without losing existing funding, a different question from the exemption-definition rulings, and the plaintiffs want an injunction less than two months before the Jan. 1, 2027 start. The enrollment-loss and funding figures come from the plaintiffs' complaint as relayed by a trade outlet, are allegations, and have not been tested in court. The legal theory's chance of success is uncertain, and the requirements remain scheduled to take effect unless a court orders otherwise.

  • Access
  • Accountability
Warrants deeper follow-up. Read the complaint (linked from the Oregon DOJ case page) and track the preliminary injunction schedule, any CMS response, and whether other states join before Jan 1, 2027.

Sources

Background from our research

Storylines

Litigation

Federal court lifts CMS freeze on new ACA broker registrations during open enrollment

Preliminary relief Nov 5, 2026 (D. Md.); open enrollment began Nov 1

What changed

The U.S. District Court for the District of Maryland granted preliminary relief on Nov. 5, 2026 to the National Association of Benefits and Insurance Professionals (NABIP) and Health Agents for America (HAFA), lifting CMS's moratorium on new agent and broker registrations for HealthCare.gov plan year 2027. Healthcare Dive reports the court agreed with NABIP's argument that CMS skipped public comment under the Administrative Procedure Act and with HAFA's argument that CMS did not consider financial harm, and found irreparable harm and public-interest grounds for relief. Newly eligible brokers could begin training on Nov. 6. Becker's reports the freeze affected about 19,000 agents and brokers and that CMS had estimated broker noncompliance could cause $1.5 billion to $6.6 billion in annual improper federal spending, depending on method; CMS imposed the freeze alongside cancellation of 2026 policies covering 760,000 people. Neither article reports a CMS response or names the judge.

Why it matters

Brokers help many consumers choose and enroll in marketplace plans, so the order restores a source of enrollment help during open enrollment. It also tests how far CMS can act against suspected enrollment fraud without notice-and-comment rulemaking. The fraud and improper-payment figures are CMS's own estimates relayed by secondary sources, the relief is preliminary, and CMS could appeal or re-issue the policy through rulemaking.

  • Access
  • Accountability
Warrants deeper follow-up. Obtain the court order and docket to confirm the judge, wording of the relief and any stay or appeal; check whether CMS responds with new rulemaking or added broker safeguards.

Sources

Background from our research

Storylines

Report

After the Nov. 3 midterms, Democratic gains in Congress; analysts expect oversight, not quick statutory change, on health policy

Election Nov 3, 2026; new Congress seated January 2027; government funding expires Dec 11

What changed

Advisory Board's Nov. 4 summary reports Democrats gained at least 12 House seats and at least 7 Senate seats, with some races uncalled, putting them on track to control both chambers. HFMA's analysis, updated Nov. 6, reports Democrats won control of Congress while Republicans keep enough Senate seats to block bills and President Trump keeps veto power. KFF's analysis of its 2026 Voter Poll (SSRS, fielded Oct. 19 to Nov. 3) found 49% of midterm voters said Democrats were better able to handle health care versus 30% for Republicans, and 54% said Trump administration policies made their own health care costs worse versus 10% better. Analysts quoted by HFMA and Advisory Board expect the Medicaid work requirements and other 2025 reconciliation-law changes to proceed largely on schedule in early 2027, and expect Democrats to focus on oversight of HHS, CMS, the administration's drug-pricing agreements, the 340B rebate model and the AI-based prior authorization pilot, with prior authorization, physician payment and No Surprises Act changes named as possible bipartisan areas. These are expectations, not enacted policy.

Why it matters

A divided government changes who can hold hearings and investigations into the agencies behind the policies this site tracks, but analysts quoted expect a presidential veto and the Senate filibuster to limit legislation, so near-term effects on coverage rules are likely to come through oversight and implementation delays rather than new law. The seat counts were incomplete as of Nov. 4 and final results were not verified. The KFF poll measures voter perceptions, and its report does not give sample size or margin of error; the policy forecasts are analysts' opinions.

  • Accountability
  • Reform
  • Affordability
Warrants deeper follow-up. Confirm final seat counts and committee leadership once races are called; track the Dec. 11 funding deadline and any hearings on Medicaid implementation, drug-pricing deals, Medicare Advantage and the AI prior-authorization pilot.

Sources

Background from our research

Storylines

Report

KFF: fewer Medicare Advantage drug-plan choices in 2027, with 193 counties lacking any MA-PD option

KFF analysis first published Oct 9, 2026 and updated Nov 5; Medicare open enrollment runs through Dec 7, 2026

What changed

KFF's analysis of CMS plan landscape files reports that the average Medicare beneficiary can choose from 28 Medicare Advantage prescription drug (MA-PD) plans from seven firms in 2027, one fewer firm than in 2026. The share of beneficiaries with more than 40 MA-PD options falls from 27% (16.6 million) to 20% (nearly 13 million), while nearly 7 million have only 1 to 10 plans, up from 4.8 million. Some 193 counties have no MA-PD available for general enrollment, up from 123, affecting 638,000 beneficiaries (about 1%), and 259 counties have just one firm, up from 180. KFF reports UnitedHealth is leaving 228 counties and entering 9, Humana leaving 62 and entering 4, Health Care Service Corporation leaving 498 and entering none, and Centene leaving 359 and entering 15, while Devoted Health enters 342 counties and leaves none. Molina and Clear Spring are exiting the MA-PD market, though Molina will keep offering special needs plans. The analysis excludes special needs plans, MA-only plans and Connecticut.

Why it matters

Fewer firms and plans per county narrows choice for the roughly half of Medicare beneficiaries who are in Medicare Advantage, during the open enrollment window when people with exiting plans must pick new coverage. Plan counts do not show differences in networks, benefits, prior authorization or quality, and the counts cover only drug-covering general-enrollment plans. This item rests on a single KFF analysis whose original version predates the briefing window; it is included because of the Nov. 5 update.

  • Access
  • Affordability

Sources

Background from our research

Storylines

Prioritized Follow-Up

  1. 2027 hospital outpatient final rule: confirm the Federal Register text and the survey basis for the 340B payment cut, and watch for hospital litigation before the Jan. 1, 2027 effective date.
  2. Medicaid work requirements: the Oregon-led suit (D. Or.) asks for a preliminary injunction less than 60 days before the Jan. 1, 2027 start, on top of the Oct. 29 Boston ruling on the 'medically frail' exemption.
  3. ACA open enrollment: watch for a CMS appeal or new rulemaking on the broker freeze, and for early plan-selection data against KFF and CBO projections.
  4. New Congress: track the Dec. 11 government funding deadline and which health oversight and bipartisan bills (prior authorization, physician payment, No Surprises Act) advance.

← All Weekly Briefings